SAG
NRIX icon

SageView Advisory Group’s Nurix Therapeutics NRIX Stock Holding History

SageView Advisory Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$608 Buy
+32
New +$460 ﹤0.01% 2430

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SageView Advisory Group's NRIX Position: Q4 2025 in Review

SageView Advisory Group opened a new position in Nurix Therapeutics (NRIX) in Q4 2025: 32 shares worth $608. The stake represents ﹤0.01% of the portfolio and ranks #2430 among its holdings.

182 funds tracked by Wall St. Rank hold NRIX as of Q4 2025.

  • SageView Advisory Group held 32 shares of Nurix Therapeutics worth $608 as of Q4 2025.
  • Nurix Therapeutics was a new SageView Advisory Group position in Q4 2025.
  • Nurix Therapeutics made up ﹤0.01% of SageView Advisory Group's portfolio in Q4 2025, its #2430 holding.
  • 182 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.